Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Discovery of anti-cancer genes could improve NHS treatment

  • Comment

Gene-screening has been used to identify women most likely to benefit from one type of breast cancer chemotherapy.

The technique could lead to a simple test enabling doctors to administer personalised treatment, say researchers.

In future the same method may offer a way of predicting which patients will respond to other cancer drugs.

This in turn could make expensive new treatments more cost-effective and available on the NHS, say researchers.

The international team of scientists scanned 829 genes in breast cancer tumour cells.

They selected six which, if missing or faulty, would prevent the chemotherapy agent paclitaxel working properly.

A patient study then showed how the genes could reveal in advance which women were likely to respond best to the drug.

Lead researcher Dr Charles Swanton, from the Cancer Research UK charity’s London Research Institute, said: “Our research shows it is now possible to rapidly pinpoint genes which prevent cancer cells from being destroyed by anti-cancer drugs and use these same genes to predict which patients will benefit from specific types of treatment.”

Each year more than 45,500 women are diagnosed with breast cancer in the UK, and around 12,000 die from the disease. About 15% of these patients will be prescribed paclitaxel.

The new findings, reported in The Lancet Oncology medical journal today, suggest that half the women currently prescribed the drug could do without it.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.